Certara Reappointed for a European Medicines Agency Contract, Expanding Opportunities to Shape the Future of Real-World Evidence for Regulatory Decision-Making
Certara was reappointed to a 4 year EMA and ECDC framework contract to generate real-world…
CertaraJune 11, 2026
Translating Targeted Radiotherapies from Mouse to Human Using QSP: A Pluvicto Case Study
Download this poster to see how Certara used quantitative systems pharmacology (QSP) to translate ¹⁷⁷Lu-PSMA-617…
CertaraJune 9, 2026
Population Pharmacokinetic Modeling to Predict Absorbed and Biologically Effective Dose for Radioligand Therapies
Explore how population PK modeling predicts absorbed dose and biologically effective dose for radioligand therapies.
CertaraJune 9, 2026
Beyond Compliance: What ICH M15 Means for the Future of Drug Development
Explore how ICH M15 is shaping regulatory expectations for Model-Informed Drug Development (MIDD), including model…
CertaraJune 9, 2026
The Case for Simulating Pregnancy
Pregnant women are routinely excluded from drug trials, leaving clinicians without dosing guidance. Discover how…
CertaraJune 9, 2026
Model-Informed Development Accelerates Transformative Treatment for Sleeping Sickness
Certara’s drug development support enabled a positive scientific opinion from the EMA for acoziborole, a…
CertaraJune 2, 2026
Oxford Academic, Neuro-Oncology Pediatrics – BRAF pub: Growth recovery in patients with BRAF-altered pediatric low-grade glioma following treatment with tovorafenib
This publication reports a pooled retrospective analysis evaluating growth patterns in children with B-Raf proto-oncogene…
Dorottya Gui-BodnarMay 28, 2026
Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models
This publication describes the development of an updated population pharmacokinetic (PopPK) model for niraparib, a…
CertaraMay 21, 2026
